Table 1.
Baseline Demographic and Clinical Characteristics
| Variable, n (%), mean (SD), or median (Q1, Q3) | Cohort, n = 1118 | SWAD, n = 234 | STAY, n = 884 | P Valuea |
|---|---|---|---|---|
| Age, years | 48.8 (8.8) | 49.8 (8.9) | 48.6 (8.7) | .06 |
| Race/ethnicity | … | … | … | .09 |
| African American (non-Hispanic) | 680 (60.8) | 140 (59.8) | 540 (61.1) | … |
| White & Other | 172 (15.4) | 46 (19.7) | 126 (14.3) | |
| Hispanic | 266 (23.8) | 48 (20.5) | 218 (24.7) | |
| Education ≤ high school | 741 (66.6) | 146 (62.7) | 595 (67.7) | .15 |
| Income ≤$12 000/year | 555 (51.2) | 114 (49.4) | 441 (51.6) | .54 |
| Has health insurance | 1079 (97.0) | 228 (97.9) | 851 (96.8) | .41 |
| Alcohol consumption, n = 1110 | … | … | … | .56 |
| Abstainer | 706 (63.6) | 149 (64.2) | 557 (63.4) | |
| 0–7 drinks/week | 324 (29.2) | 70 (30.2) | 254 (28.9) | |
| >7 drinks/week | 80 (7.2) | 13 (5.6) | 67 (7.6) | |
| Current smoker | 382 (34.4) | 68 (29.3) | 314 (35.8) | .07 |
| Time since ART initiation, years | 10.9 (5.8, 14.2) | 11.5 (6.2, 14.7) | 10.8 (5.6, 14.1) | .9 |
| Mean CD4 count, cells/mm3 | 669 (294) | 688 (295) | 664 (294) | .27 |
| Baseline viral load <200 copies/ml | 1068 (95.5) | 218 (93.2) | 850 (96.2) | .05 |
| Baseline ART regimen contains | ||||
| Non-nucleoside reverse transcriptase inhibitor | 555 (49.6) | 83 (35.5) | 472 (53.4) | <.0001 |
| Protease inhibitor | 572 (51.2) | 161 (68.8) | 411 (46.5) | <.0001 |
| Abacavir | 215 (19.2) | 64 (27.4) | 151 (17.1) | .0004 |
| Tenofovir disoproxyl fumarate | 864 (77.3) | 152 (65.0) | 712 (80.5) | <.0001 |
Bolded values in Table 1 signify statistical significance at P <.05. Age, mean CD4 count, and baseline viral load are reported as mean (SD); race/ethnicity, education, income, health insurance, alcohol consumption, current smoker, baseline ART regimen are reported as n (%); and time since ART initiation is median, Q1, Q3.
Abbreviations: Abbreviations: ART, antiretroviral therapy; INSTI, integrase strand transfer inhibitor; Q1, first quartile; Q3, third quartile; SD, standard deviation; STAY, women who remained on non-INSTI ART during follow-up; SWAD, women who switched to or added an INSTI to ART.
aThe statistical comparison between STAY and SWAD groups was conducted using Chi square tests for categorical variables and 2-sided, 2-sample t-tests for continuous variables.